Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Medipharm Labs Corp
T.LABS
Alternate Symbol(s):
MEDIF
Healthcare
Cannabis
MediPharm Labs Corp. is a Canada-based full-service pharmaceutical company. The Company specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products. Through its wholesale and white label platforms, the Company formulates, develops (including through sensory testing), processes,...
packages and distributes cannabis extracts and advanced cannabinoid-based products to domestic and international markets. It also provides GMP flower sourcing, packaging, and distribution services for select international clients. In addition, it cultivates cannabis to sell as dried flower, pre-roll and other cannabis products for the adult use and medical markets. It also sells metered dose inhalers and aerosol sublingual sprays. Through Harvest Medicine, it provides clinic services to Canadian patients requiring medical cannabis education and prescriptions.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (TSX:LABS)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
(100)
•••
Solid1
X
View Profile
View Bullboard History
Post by
Solid1
on Sep 02, 2024 5:45am
ANDA - 505(b)(2)
The most important point for me was that Jazz/GW Pharma's exclusive rights to New Chemical Entities (NCEs) expired in September 2023, just as Labs' pharma partner was filing its ANDA.
(7)
•••
Hunter34
X
View Profile
View Bullboard History
Comment by
Hunter34
on Aug 30, 2024 4:15pm
RE:Rescheduling could be Positive turn of Events :) $$$
lol
(7)
•••
Hunter34
X
View Profile
View Bullboard History
Comment by
Hunter34
on Aug 30, 2024 4:12pm
RE:Rescheduling could be Positive turn of Events :) $$$
USA will never give up on their Criminal War On Drugs and Humanity...end them...
(645)
•••
1hot-techwoman
X
View Profile
View Bullboard History
Post by
1hot-techwoman
on Aug 29, 2024 8:21pm
Rescheduling could be Positive turn of Events :) $$$
https://www.youtube.com/watch?v=zha2WEJSKoE
(137)
•••
subaru1
X
View Profile
View Bullboard History
Comment by
subaru1
on Aug 29, 2024 10:52am
RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Lots of good gouge in this article.
It seems anyway that this Reschedule has no end, it has been almost 3 years now that it is in process and other than having discussions and more discussion and waiting after this and that the schedule
...more
(100)
•••
Solid1
X
View Profile
View Bullboard History
Comment by
Solid1
on Aug 29, 2024 5:20am
RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Lots of good gouge in this article.
I also think it's beneficial for Medipharm Labs to keep cannabis on Schedule 1 in the US, because if their generic of Epidiolex is approved, it would automatically be on Schedule 5, just like
...more
(100)
•••
Solid1
X
View Profile
View Bullboard History
Comment by
Solid1
on Aug 27, 2024 4:24pm
RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Lots of good gouge in this article.
There is also a Pre IND for a 505 (b)(2) application that you submit to the FDA first. And yes, the ANDA application is for Epidiolex, but as a new indication and for guidance for the drug Epidiolex
...more
(131)
•••
QContinuum1
X
View Profile
View Bullboard History
Comment by
QContinuum1
on Aug 27, 2024 3:42pm
RE:RE:RE:RE:RE:RE:RE:RE:RE:Lots of good gouge in this article.
ANDA = Epidiolex Investigational NDA apparently = Keck trial That is all.
(100)
•••
Solid1
X
View Profile
View Bullboard History
Comment by
Solid1
on Aug 27, 2024 2:13pm
RE:RE:RE:RE:RE:RE:RE:RE:Lots of good gouge in this article.
The ANDA filing can only be a 505(b)(2) filing, which is the equivalent of an NDA. That's how it's presented in the investor presentation. And Pidduck talked about the application and referred
...more
(131)
•••
QContinuum1
X
View Profile
View Bullboard History
Comment by
QContinuum1
on Aug 27, 2024 10:49am
RE:RE:RE:RE:RE:RE:RE:Lots of good gouge in this article.
Repeat after me, there is no NDA apart from the investigational NDA.
(100)
•••
Solid1
X
View Profile
View Bullboard History
Comment by
Solid1
on Aug 27, 2024 9:17am
RE:RE:RE:RE:RE:RE:Lots of good gouge in this article.
That is not the point. The NDA/ ANDA filings that Pidduck spoke about in a conference call are completely different regulatory filings from a pharma partner for whom Medipharm supplies the active
...more
(131)
•••
QContinuum1
X
View Profile
View Bullboard History
Comment by
QContinuum1
on Aug 27, 2024 8:55am
RE:RE:RE:RE:RE:Lots of good gouge in this article.
Keck is phase 2 and may as well be eons away in terms of completion. It won't do LABS any good for a long while. If the Keck trial is indeed the investigational NDA referenced, there is no
...more
(100)
•••
Solid1
X
View Profile
View Bullboard History
Comment by
Solid1
on Aug 27, 2024 4:39am
RE:RE:RE:RE:Lots of good gouge in this article.
USC (University of Southern California) Keck School of Medicine Treatment of Alzheimer's agitation disorder Phase 2 approval by the FDA for an investigational new drug (IND) Clinical
...more
(615)
•••
okgonow
X
View Profile
View Bullboard History
Comment by
okgonow
on Aug 26, 2024 2:49pm
RE:RE:RE:Lots of good gouge in this article.
if things have not turned arround in tearms of SP by the time the next AGM vote on management and stock options is. I will be a firm NO vote on both!!!!!!!!!!!!!!!!!!!! Pidduck and crew has had
...more
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >